Calculating accurate IOL power in infants

Article

Intraocular lens (IOL) power, following primary lens implantation in infants, can be calculated reasonably accurately using current formulae, according to a report published online (December 2006) ahead of print in the British Journal of Ophthalmology.

Intraocular lens (IOL) power, following primary lens implantation in infants, can be calculated reasonably accurately using current formulae, according to a report published online (December 2006) ahead of print in the British Journal of Ophthalmology.

Jane Ashworth and colleagues from the Manchester Royal Eye Hospital, UK, conducted a retrospective case review of 25 patients (eight with bilateral cataracts and 17 with unilateral) who underwent cataract surgery with primary IOL implantation at less then 12 months of age. The outcomes measured were actual early-postoperative refraction, lens power calculation error, myopic shift and refractive outcome.

In 83% of cases, actual postoperative refraction was within 2 D of target refraction. The researchers found that lens power calculation error did not depend on axial length, age at surgery or target refraction. The mean myopic shift was 5.43±3.7 D in the first 12 months following surgery, but was significantly greater where surgery was performed at less than 10 weeks of age.

The researchers found that, using current formulae, IOL power can be calculated with reasonable accuracy.

Recent Videos
Thomas Aaberg, MD, gives an update on Neurotech Pharmaceuticals NT-501 device for the potential treatment of retinitis pigmentosa and age-related macular degeneration, including a projected PDUFA date from the FDA at the annual ASRS meeting in Stockholm, Sweden.
Sruthi Arepalli, MD, spoke with Modern Retina about her presentation, "Assessing retinal vascular changes in alzheimer disease with radiomics: A preliminary study of fundus photography" at the annual ASRS meeting in Stockholm, Sweden.
Nathan Steinle, MD, spoke with Modern Retina about the ongoing research on the durability of sozinibercept in combination therapy with anti-VEGF-A treatments at the annual ASRS meeting in Stockholm, Sweden.
Deepak Sambhara, MD, shared an overview of his paper-on-demand, which covered real-world safety and efficacy of aflibercept, 8 mg in the treatment of neovascular age-related macular degeneration at the annual ASRS meeting in Stockholm, Sweden.
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
© 2024 MJH Life Sciences

All rights reserved.